Survival outcomes of patients diagnosed with muscle-invasive bladder cancer who showed a response after neoadjuvant chemotherapy and refused radical cystectomy, and patients who had radical cystectomy or received chemoradiotherapy

Basit Öğe Kaydı
dc.contributor.authorTunc, Sezai
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorEbinc, Senar
dc.contributor.authorIleri, Serdar
dc.contributor.authorKalkan, Ziya
dc.contributor.authorOruc, Zeynep
dc.contributor.authorKucukoner, Mehmet
dc.date.accessioned2024-04-24T17:27:57Z
dc.date.available2024-04-24T17:27:57Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction. We aimed to compare the survival results of patients with muscle-invasive bladder cancer who responded after neoadjuvant chemotherapy (NAC) and did not accept further treatment and those who underwent radical cystectomy or received chemoradiotherapy (CRT).Material and methods. The study included 53 patients with non-metastatic muscle-invasive bladder cancer who received NAC between 2009 and 2020. Clinical findings and post-NAC survival analysis were evaluated. Survival analyses of patients who underwent radical cystectomy (RC) after NAC, received CRT, and refused treatment were compared.Results. The median age at diagnosis was 61 (33-80) years. After NAC, 18 patients (34%) received CRT, 9 patients (17%) underwent RC, and 18 patients (34%) refused further treatment. Complete response (CR) was present in 10 (18.4%) patients, partial response (PR) in 35 (66%) patients, stable disease (SD) in 1 (1.9%) patient, and progression in 7 (13.2%) patients. Median overall survival (OS) was 78 months. Median OS was not reached in the RC arm; it was 97 months in the CRT arm and 78 months in the declined-treatment arm. There was no statistical difference between the arms (p = 0.94). Median disease-free survival (DFS) was 32 months. Median DFS in the RC arm was 30 months, in the CRT arm - 34 months, and 28 months in the declined-treatment arm after NAC. There was no statistically significant difference between the arms (p = 0.74).Conclusions. We did not find any difference in terms of OS and DFS between patients who after NAC underwent RC, CRT, or refused treatment.en_US
dc.identifier.doi10.5603/OCP.2023.0030
dc.identifier.endpage338en_US
dc.identifier.issn2450-1654
dc.identifier.issn2450-6478
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-85175628259
dc.identifier.scopusqualityQ4
dc.identifier.startpage331en_US
dc.identifier.urihttps://doi.org/10.5603/OCP.2023.0030
dc.identifier.urihttps://hdl.handle.net/11468/20269
dc.identifier.volume19en_US
dc.identifier.wosWOS:001094605100001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherVia Medicaen_US
dc.relation.ispartofOncology in Clinical Practice
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChemoradiotherapyen_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.subjectMuscle-Invasive Bladder Canceren_US
dc.subjectRadical Cystectomyen_US
dc.subjectRefused Treatmenten_US
dc.titleSurvival outcomes of patients diagnosed with muscle-invasive bladder cancer who showed a response after neoadjuvant chemotherapy and refused radical cystectomy, and patients who had radical cystectomy or received chemoradiotherapyen_US
dc.titleSurvival outcomes of patients diagnosed with muscle-invasive bladder cancer who showed a response after neoadjuvant chemotherapy and refused radical cystectomy, and patients who had radical cystectomy or received chemoradiotherapy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu